- Home
- MATH vs MIST Comparison
MATH vs MIST Comparison
Compare MATH & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATH
- MIST
- Stock Information
- Founded
- MATH 2015
- MIST 2003
- Country
- MATH Hong Kong
- MIST Canada
- Employees
- MATH N/A
- MIST N/A
- Industry
- MATH Finance/Investors Services
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- MATH Finance
- MIST Health Care
- Exchange
- MATH Nasdaq
- MIST Nasdaq
- Market Cap
- MATH 60.8M
- MIST 53.9M
- IPO Year
- MATH N/A
- MIST N/A
- Fundamental
- Price
- MATH $2.33
- MIST $1.12
- Analyst Decision
- MATH
- MIST Strong Buy
- Analyst Count
- MATH 0
- MIST 2
- Target Price
- MATH N/A
- MIST $9.50
- AVG Volume (30 Days)
- MATH 84.8K
- MIST 1.6M
- Earning Date
- MATH 01-01-0001
- MIST 05-20-2025
- Dividend Yield
- MATH N/A
- MIST N/A
- EPS Growth
- MATH N/A
- MIST N/A
- EPS
- MATH 0.17
- MIST N/A
- Revenue
- MATH $31,399,049.00
- MIST N/A
- Revenue This Year
- MATH N/A
- MIST N/A
- Revenue Next Year
- MATH N/A
- MIST N/A
- P/E Ratio
- MATH $11.51
- MIST N/A
- Revenue Growth
- MATH 291.58
- MIST N/A
- 52 Week Low
- MATH $0.80
- MIST $0.63
- 52 Week High
- MATH $2.78
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- MATH 66.41
- MIST 46.48
- Support Level
- MATH $1.85
- MIST $1.28
- Resistance Level
- MATH $2.08
- MIST $1.32
- Average True Range (ATR)
- MATH 0.17
- MIST 0.12
- MACD
- MATH 0.05
- MIST 0.03
- Stochastic Oscillator
- MATH 95.65
- MIST 38.80
About MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).